Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 107 Show results per page	View Search Criteria \| Help With Results


1.		Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Other				HFHS 05-03 NCT00448240

Last Modified: 10/24/2008 First Published: 7/23/2004


2.		Phase III Randomized Study of Docetaxel With or Without Gefitinib in Patients With Metastatic or Locally Recurrent Squamous Cell Carcinoma of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ECOG-E1302 E1302, NCT00088907

Last Modified: 10/10/2008 First Published: 10/25/2004


3.		Phase III Randomized Study of Induction Chemotherapy Comprising Docetaxel, Cisplatin, and Fluorouracil Followed By Radiotherapy and Carboplatin or Docetaxel Versus Radiotherapy and Cisplatin Only in Patients With Previously Untreated Stage III or IV Squamous Cell Carcinoma of the Head and Neck (Paradigm Trial)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Over 18				NCI, Pharmaceutical / Industry				DFCI-04006 AVENTIS-DFCI-04006, NCT00095875, PARADIGM TRIAL


4.		Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				IRB 13362B NCT00117572

Last Modified: 10/24/2008 First Published: 12/9/2005


5.		Phase III Randomized Study of Concurrent Accelerated Fractionated Radiotherapy and Cisplatin With Versus Without Cetuximab in Patients With Stage III or IV Squamous Cell Carcinoma of the Oropharynx, Hypopharynx, or Larynx

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				RTOG-0522 RTOG 0522, RTOG-0522, NCT00265941


6.		A Study for Patients With Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				8431 H3E-MC-JMHR, NCT00415194


7.		Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				Pharmaceutical / Industry				EGF102988 NCT00424255


8.		SPECTRUM: Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				20050251 SPECTRUM, 20050251, NCT00460265

Last Modified: 10/24/2008 First Published: 12/27/2007


9.		Phase III Randomized Study of Cisplatin-Containing Chemotherapy With Versus Without Bevacizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ECOG-E1305 E1305, NCT00588770

Last Modified: 10/3/2008 First Published: 1/29/2008


10.		Phase III Randomized Study of Radiotherapy and Cisplatin With Versus Without Fluorouracil in Patients With Stage III or IV Squamous Cell Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				CASE-3307-CC389 CASE-3307, CASE-CC389, CASE3307-CC389, NCT00608205

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute